Skip to main content
. 2014 Jul;58(7):4014–4019. doi: 10.1128/AAC.02521-14

TABLE 2.

Microbiologic cure at visit 3 and visit 4 (mITT population)

Visit, clinical response Result for subjects receiving:
Rifalazil−azithromycin
Rifalazil, 25 mg Azithromycin, 1 g
Visit 3
    Total no. of subjects 33 38
    No. (%) cured 28 (84.8) 35 (92.1) (−7.3)
    No. (%) failed 5 (15.2) 3 (7.9)
    95% CI (72.4; 97.3) (83.4; 100.0) (−22.5; 7.9)
Visit 4
    Total no. of subjects 33 38
    No. (%) cured 26 (78.8) 31 (81.6) (−2.8)
    No. (%) failed 7 (21.2) 7 (18.4)
    95% CI (64.6; 93.0) (69.0; 94.1) (−21.7; 16.1)